This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Distribution of secretory inhibitor of platelet microbicidal
protein among urethral isolates with its correlation with
prostatitis
Iuri B. Ivanov, Viktor A. Gritsenko, Michael D. Kuzmin
Department of Human Microbiology, Institute of Cellular and Intracellular Symbiosis, Russian Academy of Sciences,
Orenburg 460056, Russia
Abstract
Aim: To report the detection in
vitro of secretory inhibitor of platelet microbicidal protein (SIPMP) phenotypes of
urethral isolates along with a comparison with isolates from patients with or without chronic bacterial prostatitis
(CBP). Methods: Urethral isolates of
Staphylococcus spp. (n = 64), diphtheroids
(n = 28), micrococci
(n = 15), streptococci
(n = 21),
Enterobacteriaceae (n = 9) and
Enterococcus faecalis
(n = 19) from patients with or without
CBP were tested. SIPMP production was tested by inhibition of platelet microbicidal protein (PMP) bioactivity against
Bacillus subtilis and was expressed as percentage of inhibition of PMP bactericidal
activity. Results: A significantly higher proportion of CBP-strains (57.78%
vs. 16.67%) reduced PMP-induced killing of
Bacillus subtilis than non-CBP strains did
(P < 0.01). SIPMP levels of staphylococci and
Enterococcus faecalis from the CBP group were
significantly higher than those of the control
group. Conclusion: These results suggest that SIPMP production is
associated with the CBP source. Data from the present study might have significant implications for the understanding
of the pathogenesis of CBP. (Asian J Androl 2008 Mar; 10: 189_192)
Keywords: bacteriology; platelet microbicidal protein; prostatitis
Correspondence to: Dr Iuri B. Ivanov, Volgogradskaya Street, 36/3, Office.93, Orenburg 460056, Russia.
Tel: +7-35-3277-5417 Fax: +7-35-3277-4463
E-mail: ubi@mail.orb.ru
Received 2007-06-04 Accepted 2007-08-23
DOI: 10.1111/j.1745-7262.2008.00344.x
1 Introduction
A number of microorganisms are able to infect the reproductive tract tissues in humans with serious
consequences for reproductive function [1, 2]. A most common result of microbial infection of the reproductive tract is
chronic bacterial prostatitis (CBP), a condition that can lead to transient or permanent infertility [1_3]. CBP is a subtle
illness, which is characterized by persistence of bacteria in the prostatic secretory system [2, 3]. As it is difficult to
establish precisely the significance of various microorganisms in the pathogenesis of CBP, it is imperative to delineate
both microbial and host factors that contribute to its development [1, 3, 4].
The major role of endogenous cationic antimicrobial peptides in preventing the onset of infection has been
emphasized recently [5, 6]. Such peptides have also been found by several authors in human platelets and are
designated beta-lysins [7], thrombocidins [8] and platelet microbicidal protein (PMP) [9, 10]. These peptides are
secreted at sites of infection and exert microbicidal activity against many pathogens [7_10]. We have shown that
resistance of urethral staphylococcal and enterococcal strains to human PMP
in vitro correlates with the diagnosis of CBP [10]. In a recent publication [11], we reported the detection of an extracellular
staphylococcal product, designated secretory inhibitor of platelet microbicidal protein
(SIPMP), that causes local inhibition of the bactericidal
action of PMP in the fluid phase. We also demonstrated
that SIPMP represents a hitherto unrecognized
determinant of staphylococcal pathogenicity and SIPMP
production is associated with prostatitis source.
The present study reports the detection in
vitro of SIPMP phenotypes of urethral isolates along with a
comparison with isolates from patients with or without CBP.
2 Materials and methods
Platelet microbicidal protein was prepared and
standardized as described previously [10].
Well-characte-rized urethral isolates of microorganisms
(n = 156) from patients with or without CBP were kindly provided by
Serge Cherkasov (Orenburg State Medical Academy, Orenburg, Russia). The determination of patients and
cases from which the isolates were initially obtained as
CBP, and non-CBP were made by the contributing investigator, using standard clinical parameters, prior to
knowledge of an isolate's SIPMP production. SIPMP
production was tested according to the recently proposed
procedures [11].
The mean values and standard mean errors were calculated. The proportion of CBP and non-CBP isolates
with different levels of SIPMP was compared and
differences between groups were assessed using unpaired
t-test. P < 0.05 was considered significant.
3 Results
Exposure of 108 washed human platelets per mL
to 5 mL of ice-cold 30% acetic acid resulted in mean
supernatant protein concentrations of
approximately 70 mg/mL. The bioactivity of such PMP preparations
against Bacillus subtilis ranged from 0.5 µg/mL to
1.0 µg/mL. Control samples were found to possess no
anti-B. subtilis bioactivity.
Among the 64 Staphylococcus spp. isolates studied,
39 urethral isolates were from patients with CBP, and 25
isolates were from patients without CBP (Table 1). Of
the CBP-strains tested, 51.3% were found to produce
SIPMP compared with only 20% (P < 0.01) of the
non-CBP isolates. Of the 28 urethral diphtheroids isolates tested,
11 and 17 were from CBP and non-CBP cases, respectively.
A significantly higher proportion of CBP strains of
diphtheroids (63.6% vs.11.76%;
P < 0.001) was SIPMP-positive compared with non-CBP strains. Among
SIPMP-producing strains of micrococci tested, 20% of
isolates were from the control group, whereas 40% of
isolates were from patients with CBP. Of the 21 urethral
streptococcal isolates studied, 10 were from patients
without clinical symptoms of CBP, whereas 11 were from
patients with CBP. We found no significant difference
in the proportion of SIPMP-positive streptococcal
isolates between the two groups.
The extracellular products of bacteria reduced the
bioactivity of PMP (Tables 2 and 3). In contrast to bacteria
isolated from the control group, the strains isolated from
men with CBP demonstrated more intensive inhibition of
PMP-induced killing of B. subtilis. The culture
supernatants of staphylococci from the CBP group significantly
more actively decreased bioactivity of PMP
(P < 0.05). SIPMP-production of diphtheroids, micrococci and
streptococci from men with CBP were not significantly
different from strains of bacteria isolated from anterior
urethra of healthy men (P > 0.05).
4 Discussion
Chronic bacterial prostatitis is characterized by
recurrent urinary tract infections and persistence of
bacteria in the prostatic secretory system, despite the
presence of multiple antibacterial peptides in prostatic fluid
[12, 13]. There is an urgent need to understand the
virulence properties of bacteria that are associated with
chronic infection of the prostate. Identifying such
factors would be helpful in devising effective treatment
strategies.
In the present work, we detected an extracellular
bacterial product with remarkable anti-PMP potential. As
PMP might play an important role in the killing of
diffe-rent bacterial pathogens and in preventing the onset of
bacterial infection of the prostate, we speculated that
SIPMP serves to protect invading bacteria by inducing
local consumption of PMP in the fluid phase. The
stra-tegy underlying this process is straightforward and should
be effective. We believe that SIPMP represents a
widespread and hitherto unrecognized determinant of
bacterial pathogenicity. Similarly, in a study of the
distribution of streptococcal inhibitor of complement variants in
pharyngitis and invasive isolates by Hoe
et al. [14], 62% of group A Streptococci
from patients with pharyngitis produced this extracellular protein. In addition, a recent
study by Fernie-King et al. [15] shows that purified
secretory inhibitor of complement could block two
additional components of the immune system: lysozyme and
secretory leukocyte proteinase inhibitor. Collectively, our
study and the results of several studies [14_17] suggest
that the inactivation of components of innate immunity
might be important for bacterial pathogens to induce and
perpetuate chronic infections of different localization by
surviving or avoiding microbicidal protein-mediated
clearance. If this hypothesis is correct, it suggests that
organisms are capable of pronounced inhibition of PMP;
further prolonged persistence in the urethra might alter
the antimicrobial host defense of the genital tract in the
presence of chronic infections, as demonstrated for
persistent nonspecific urethritis [18]. Data from the present
study might have significant implications for the
understanding of the pathogenesis of CBP, as well as for
future improvements in the prevention and therapy of CBP.
Acknowledgment
These investigations were supported in part by a grant
from the Russian Foundation of Basic Research (No.
07-04-97624 to I. B. Ivanov).
References
1 Domingue GJ Sr, Hellstrom WJ. Prostatitis. Clin Microbiol
Rev 1998; 11: 604_13.
2 Everaert K, Mahmoud A, Depuydt C, Maeyaert M, Comhaire
F. Chronic prostatitis and male accessory gland infection _ is
there an impact on male infertility (diagnosis and therapy)?
Andrologia 2003; 35: 325_30.
3 Schoor RA. Prostatitis and male infertility: evidence and links.
Curr Urol Rep 2002; 3: 324_9.
4 Hua VN, Williams DH, Schaeffer AJ. Role of bacteria in
chronic prostatitis/chronic pelvic pain syndrome. Curr Urol
Rep 2005; 6:300_6.
5 Dürr M, Peschel A. Chemokines meet defensins: the merging
concepts of chemoattractants and antimicrobial peptides in
host defense. Infect Immun 2002; 70: 6515_7.
6 Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob
Agents Chemother 1999; 43: 1317_23.
7 Donaldson DM, Tew JG. beta-Lysin of platelet origin.
Bacteriol Rev 1977; 41: 501_13.
8 Krijgsveld J, Zaat SAJ, Meeldijk J, van Veelen PA, Fang G,
Poolman B, et al. Thrombocidins, microbicidal proteins from
human platelets, are C-terminal deletion products of CXC
chemokines. J Biol Chem 2000; 275: 20374_81.
9 Yeaman MR. The role of platelets in antimicrobial host defense.
Clin Infect Dis 1997; 25: 951_68.
10 Ivanov IB. In vitro resistance to human platelet microbicidal
protein among urethral staphylococcal and enterococcal
isolates with its correlation with prostatitis. Indian J Med
Microbiol 2005; 23: 253_5.
11 Ivanov IB, Gritsenko VA, Kuzmin MD. Staphylococcal
secretory inhibitor of platelet microbicidal protein is associated
with prostatitis source. J Med Microbiol 2006; 55:1645_8.
12 Fair WR, Parrish RF. Antibacterial substances in prostatic
fluid. Prog Clin Biol Res 1981; 75A: 247_64.
13 Com E, Bourgeon F, Evrard B, Ganz T, Colleu D, Jégou B,
et al. Expression of antimicrobial defensins in the male
reproductive tract of rats, mice, and humans. Biol Reprod 2003; 68:
95_104.
14 Hoe NP, Vuopio-Varkila J, Vaara M, Grigsby D, De Lorenzo
D, Fu YX, et al. Distribution of streptococcal inhibitor of
complement variants in pharyngitis and invasive isolates in an
epidemic of serotype M1 group A
Streptococcus infection. J Infect Dis 2001; 183: 633_9.
15 Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ.
Streptococcal inhibitor of complement inhibits two additional
components of the mucosal innate immune system: secretory
leukocyte proteinase inhibitor and lysozyme. Infect Immun 2002;
70: 4908_16.
16 Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser
JD. The staphylococcal superantigen-like protein 7 binds IgA
and complement C5 and inhibits IgA-Fc alpha RI and serum
killing of bacteria. J Immunol 2005; 174: 2926_33.
17 Deckers D, Masschalck B, Aertsen A, Callewaert I, Van Tiggelen
CG, Atanassova M, et al. Periplasmic lysozyme inhibitor
contributes to lysozyme resistance in Escherichia
coli. Cell Mol Life Sci 2004; 61: 1229_37.
18 Ivanov YB. Microbiological features of persistent
nonspecific urethritis in men. J Microbiol Immunol Infect 2007; 40:
157_61.
|